 Christina Nelson
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tularemia | 13 | 2025 | 30 | 7.250 |
Why?
| | Lyme Disease | 18 | 2024 | 61 | 6.610 |
Why?
| | Plague | 14 | 2023 | 60 | 6.520 |
Why?
| | Francisella tularensis | 12 | 2025 | 33 | 6.120 |
Why?
| | Yersinia pestis | 9 | 2023 | 45 | 4.880 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2025 | 13 | 1.650 |
Why?
| | Bioterrorism | 6 | 2025 | 31 | 1.610 |
Why?
| | Anti-Infective Agents | 4 | 2024 | 239 | 1.580 |
Why?
| | Meningitis | 2 | 2024 | 81 | 1.480 |
Why?
| | Tick-Borne Diseases | 5 | 2021 | 12 | 1.400 |
Why?
| | Cat-Scratch Disease | 2 | 2020 | 3 | 1.180 |
Why?
| | Anti-Bacterial Agents | 11 | 2025 | 1866 | 1.180 |
Why?
| | Borrelia burgdorferi | 4 | 2021 | 19 | 1.080 |
Why?
| | Zoonoses | 4 | 2024 | 38 | 0.980 |
Why?
| | Tick Bites | 3 | 2021 | 10 | 0.850 |
Why?
| | Aminoglycosides | 4 | 2024 | 26 | 0.830 |
Why?
| | Occupational Exposure | 3 | 2024 | 349 | 0.780 |
Why?
| | Ticks | 3 | 2018 | 30 | 0.770 |
Why?
| | Organ Transplantation | 2 | 2019 | 252 | 0.760 |
Why?
| | Strigiformes | 1 | 2022 | 3 | 0.750 |
Why?
| | Coinfection | 1 | 2023 | 137 | 0.730 |
Why?
| | Nurse Practitioners | 1 | 2023 | 142 | 0.690 |
Why?
| | Bartonella henselae | 1 | 2020 | 1 | 0.670 |
Why?
| | Chorioretinitis | 1 | 2020 | 8 | 0.660 |
Why?
| | Retinitis | 1 | 2020 | 21 | 0.660 |
Why?
| | Incidence | 11 | 2024 | 2806 | 0.660 |
Why?
| | United States | 20 | 2025 | 15310 | 0.640 |
Why?
| | Humans | 59 | 2025 | 141754 | 0.630 |
Why?
| | Ixodes | 2 | 2016 | 12 | 0.610 |
Why?
| | Hospital Costs | 1 | 2020 | 122 | 0.610 |
Why?
| | Diagnostic Errors | 2 | 2018 | 178 | 0.610 |
Why?
| | Government Employees | 1 | 2018 | 2 | 0.600 |
Why?
| | Parks, Recreational | 1 | 2018 | 11 | 0.590 |
Why?
| | Tetracyclines | 3 | 2024 | 14 | 0.590 |
Why?
| | Pets | 1 | 2018 | 27 | 0.580 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2021 | 240 | 0.570 |
Why?
| | Vaccines | 1 | 2023 | 406 | 0.560 |
Why?
| | Insurance, Health | 1 | 2020 | 299 | 0.540 |
Why?
| | Clothing | 1 | 2016 | 22 | 0.490 |
Why?
| | Female | 39 | 2024 | 75943 | 0.490 |
Why?
| | Syncope | 1 | 2016 | 57 | 0.480 |
Why?
| | Bradycardia | 1 | 2016 | 52 | 0.480 |
Why?
| | Male | 32 | 2024 | 70179 | 0.450 |
Why?
| | Diagnostic Test Approval | 1 | 2014 | 1 | 0.430 |
Why?
| | Infant | 12 | 2022 | 9843 | 0.430 |
Why?
| | Animals | 20 | 2025 | 37749 | 0.420 |
Why?
| | Young Adult | 15 | 2021 | 13749 | 0.410 |
Why?
| | Seasons | 5 | 2024 | 546 | 0.410 |
Why?
| | Hot Temperature | 1 | 2016 | 406 | 0.390 |
Why?
| | Dogs | 4 | 2024 | 427 | 0.390 |
Why?
| | Hodgkin Disease | 1 | 2015 | 157 | 0.390 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 197 | 0.380 |
Why?
| | Fluoroquinolones | 2 | 2024 | 43 | 0.370 |
Why?
| | Child | 15 | 2024 | 22414 | 0.360 |
Why?
| | Zika Virus | 3 | 2018 | 128 | 0.360 |
Why?
| | Adult | 22 | 2024 | 39391 | 0.360 |
Why?
| | Africa | 2 | 2023 | 119 | 0.360 |
Why?
| | Abortion, Spontaneous | 2 | 2024 | 116 | 0.350 |
Why?
| | Infant, Newborn | 9 | 2024 | 6289 | 0.350 |
Why?
| | Middle Aged | 19 | 2024 | 34647 | 0.340 |
Why?
| | Zika Virus Infection | 3 | 2018 | 165 | 0.340 |
Why?
| | Asphyxia Neonatorum | 1 | 2010 | 18 | 0.340 |
Why?
| | Central Nervous System Diseases | 1 | 2011 | 73 | 0.340 |
Why?
| | Population Surveillance | 4 | 2021 | 482 | 0.340 |
Why?
| | Hospitalization | 1 | 2020 | 2264 | 0.320 |
Why?
| | Immunocompromised Host | 1 | 2011 | 203 | 0.320 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 151 | 0.310 |
Why?
| | Clinical Competence | 1 | 2018 | 1205 | 0.310 |
Why?
| | Child, Preschool | 10 | 2020 | 11512 | 0.310 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2009 | 5 | 0.310 |
Why?
| | Peer Review, Research | 1 | 2009 | 43 | 0.290 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1344 | 0.290 |
Why?
| | Tuberculosis | 1 | 2011 | 286 | 0.280 |
Why?
| | Premature Birth | 2 | 2024 | 368 | 0.280 |
Why?
| | Resuscitation | 1 | 2010 | 283 | 0.280 |
Why?
| | Adolescent | 15 | 2020 | 22130 | 0.270 |
Why?
| | Dermatology | 1 | 2009 | 122 | 0.260 |
Why?
| | Sex Factors | 4 | 2017 | 2063 | 0.260 |
Why?
| | Guidelines as Topic | 1 | 2009 | 275 | 0.260 |
Why?
| | Disease Outbreaks | 3 | 2020 | 419 | 0.260 |
Why?
| | Age Factors | 5 | 2018 | 3294 | 0.250 |
Why?
| | Health Care Surveys | 2 | 2019 | 566 | 0.250 |
Why?
| | Influenza Vaccines | 1 | 2011 | 551 | 0.240 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1127 | 0.240 |
Why?
| | Ultrasonic Therapy | 1 | 2025 | 15 | 0.230 |
Why?
| | Lipolysis | 1 | 2025 | 46 | 0.230 |
Why?
| | Influenza, Human | 1 | 2011 | 626 | 0.220 |
Why?
| | Bartonella | 2 | 2016 | 8 | 0.220 |
Why?
| | Bartonella Infections | 2 | 2016 | 5 | 0.220 |
Why?
| | Aged | 14 | 2024 | 24746 | 0.220 |
Why?
| | Ibogaine | 1 | 2024 | 1 | 0.220 |
Why?
| | Insect Repellents | 2 | 2021 | 7 | 0.220 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2017 | 408 | 0.220 |
Why?
| | Trench Fever | 1 | 2024 | 5 | 0.220 |
Why?
| | Bartonella quintana | 1 | 2024 | 5 | 0.210 |
Why?
| | Ciprofloxacin | 1 | 2024 | 26 | 0.210 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 60 | 0.210 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 46 | 0.200 |
Why?
| | Antibodies, Bacterial | 3 | 2019 | 146 | 0.200 |
Why?
| | Fever | 2 | 2022 | 308 | 0.200 |
Why?
| | Abscess | 1 | 2024 | 77 | 0.200 |
Why?
| | History, 21st Century | 3 | 2024 | 220 | 0.200 |
Why?
| | Streptococcus | 1 | 2023 | 29 | 0.200 |
Why?
| | Chloramphenicol | 1 | 2022 | 10 | 0.200 |
Why?
| | Public Health Surveillance | 3 | 2021 | 84 | 0.190 |
Why?
| | Wyoming | 2 | 2019 | 27 | 0.190 |
Why?
| | Autopsy | 1 | 2022 | 98 | 0.180 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7923 | 0.180 |
Why?
| | Receptors, Nicotinic | 1 | 2024 | 344 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2567 | 0.180 |
Why?
| | Syndecan-1 | 1 | 2021 | 41 | 0.170 |
Why?
| | Nicotine | 1 | 2024 | 350 | 0.170 |
Why?
| | Dopamine | 1 | 2024 | 309 | 0.170 |
Why?
| | Smoke Inhalation Injury | 1 | 2021 | 30 | 0.170 |
Why?
| | Insecticides | 1 | 2021 | 42 | 0.170 |
Why?
| | Dancing | 1 | 2020 | 16 | 0.170 |
Why?
| | Insurance Claim Review | 1 | 2021 | 85 | 0.170 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 23 | 0.160 |
Why?
| | Asia | 1 | 2020 | 70 | 0.160 |
Why?
| | Databases, Factual | 2 | 2016 | 1448 | 0.160 |
Why?
| | Gentamicins | 1 | 2020 | 52 | 0.160 |
Why?
| | Pregnancy | 7 | 2024 | 7092 | 0.160 |
Why?
| | Virginia | 1 | 2019 | 64 | 0.150 |
Why?
| | Relapsing Fever | 1 | 2019 | 2 | 0.150 |
Why?
| | Caves | 1 | 2019 | 4 | 0.150 |
Why?
| | Maryland | 1 | 2019 | 63 | 0.150 |
Why?
| | Dog Diseases | 1 | 2020 | 65 | 0.150 |
Why?
| | Sentinel Surveillance | 1 | 2019 | 48 | 0.150 |
Why?
| | Hyaluronic Acid | 1 | 2021 | 230 | 0.150 |
Why?
| | Pseudomonas Infections | 1 | 2021 | 230 | 0.150 |
Why?
| | Bites and Stings | 1 | 2018 | 29 | 0.150 |
Why?
| | Odds Ratio | 1 | 2021 | 1057 | 0.140 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 168 | 0.140 |
Why?
| | Vermont | 1 | 2018 | 10 | 0.140 |
Why?
| | Semen | 1 | 2018 | 21 | 0.140 |
Why?
| | Data Collection | 1 | 2021 | 662 | 0.140 |
Why?
| | Virus Shedding | 1 | 2018 | 48 | 0.140 |
Why?
| | Blood Donors | 1 | 2019 | 115 | 0.140 |
Why?
| | Sciuridae | 1 | 2019 | 147 | 0.140 |
Why?
| | Postural Balance | 1 | 2020 | 238 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2018 | 3597 | 0.130 |
Why?
| | Muscle Strength | 1 | 2020 | 329 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 482 | 0.130 |
Why?
| | Biological Warfare | 1 | 2017 | 2 | 0.130 |
Why?
| | Water | 2 | 2021 | 466 | 0.130 |
Why?
| | Manuals as Topic | 1 | 2016 | 16 | 0.130 |
Why?
| | RNA, Viral | 2 | 2018 | 693 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2017 | 96 | 0.130 |
Why?
| | Insurance Claim Reporting | 1 | 2016 | 27 | 0.130 |
Why?
| | Nymph | 1 | 2016 | 4 | 0.130 |
Why?
| | Tinea | 1 | 2016 | 2 | 0.120 |
Why?
| | HIV Infections | 1 | 2011 | 3022 | 0.120 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 117 | 0.120 |
Why?
| | Lymphatic Diseases | 1 | 2016 | 22 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2938 | 0.120 |
Why?
| | Humidity | 1 | 2016 | 50 | 0.120 |
Why?
| | Exercise Therapy | 1 | 2020 | 454 | 0.120 |
Why?
| | Doxycycline | 1 | 2016 | 61 | 0.120 |
Why?
| | Administration, Topical | 1 | 2016 | 150 | 0.120 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 209 | 0.120 |
Why?
| | Risk Factors | 6 | 2024 | 10482 | 0.120 |
Why?
| | Tissue Donors | 1 | 2019 | 406 | 0.120 |
Why?
| | Immunoblotting | 1 | 2016 | 310 | 0.120 |
Why?
| | Laboratories | 1 | 2016 | 110 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2016 | 144 | 0.110 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 41 | 0.110 |
Why?
| | Office Visits | 1 | 2015 | 95 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1282 | 0.110 |
Why?
| | Bacterial Infections | 1 | 2017 | 245 | 0.110 |
Why?
| | Symptom Assessment | 1 | 2016 | 130 | 0.110 |
Why?
| | Public Health | 1 | 2020 | 587 | 0.110 |
Why?
| | Disease Progression | 1 | 2022 | 2800 | 0.110 |
Why?
| | Sepsis | 1 | 2021 | 621 | 0.110 |
Why?
| | Cold Temperature | 1 | 2016 | 196 | 0.110 |
Why?
| | Cross Infection | 1 | 2017 | 254 | 0.110 |
Why?
| | Culture Techniques | 1 | 2014 | 74 | 0.110 |
Why?
| | Cost of Illness | 1 | 2016 | 313 | 0.110 |
Why?
| | Nurses | 1 | 2016 | 184 | 0.110 |
Why?
| | Physicians, Primary Care | 1 | 2016 | 226 | 0.100 |
Why?
| | Myocarditis | 1 | 2014 | 100 | 0.100 |
Why?
| | Death, Sudden, Cardiac | 1 | 2014 | 191 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 212 | 0.100 |
Why?
| | Kidney Transplantation | 1 | 2019 | 678 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2017 | 585 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2019 | 715 | 0.090 |
Why?
| | Vaccination | 2 | 2012 | 1472 | 0.090 |
Why?
| | Nurseries, Hospital | 1 | 2012 | 5 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3008 | 0.090 |
Why?
| | Outpatients | 1 | 2015 | 421 | 0.090 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 43 | 0.090 |
Why?
| | Hepatitis B | 1 | 2012 | 69 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5697 | 0.090 |
Why?
| | Nepal | 1 | 2010 | 31 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1317 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 40 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5974 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1757 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2020 | 16374 | 0.080 |
Why?
| | Lung | 2 | 2021 | 4137 | 0.080 |
Why?
| | Bacteremia | 1 | 2012 | 216 | 0.080 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2012 | 186 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2903 | 0.070 |
Why?
| | Health Policy | 1 | 2012 | 405 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1570 | 0.070 |
Why?
| | Colombia | 2 | 2017 | 41 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2010 | 854 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2017 | 309 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3356 | 0.060 |
Why?
| | Sex Distribution | 2 | 2016 | 381 | 0.050 |
Why?
| | Nicotinic Antagonists | 1 | 2024 | 36 | 0.050 |
Why?
| | Colorado | 2 | 2012 | 4629 | 0.050 |
Why?
| | Xenopus laevis | 1 | 2024 | 107 | 0.050 |
Why?
| | Self Administration | 1 | 2024 | 126 | 0.050 |
Why?
| | Oocytes | 1 | 2024 | 179 | 0.050 |
Why?
| | Interneurons | 1 | 2024 | 124 | 0.050 |
Why?
| | Nicotinic Agonists | 1 | 2024 | 136 | 0.050 |
Why?
| | Nucleus Accumbens | 1 | 2024 | 151 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2024 | 295 | 0.040 |
Why?
| | Glycocalyx | 1 | 2021 | 29 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2025 | 647 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2021 | 149 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2021 | 171 | 0.040 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 42 | 0.040 |
Why?
| | Anorexia | 1 | 2020 | 17 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 289 | 0.040 |
Why?
| | Animals, Domestic | 1 | 2019 | 16 | 0.040 |
Why?
| | Random Allocation | 1 | 2020 | 367 | 0.040 |
Why?
| | New Mexico | 1 | 2020 | 104 | 0.040 |
Why?
| | Permethrin | 1 | 2019 | 1 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2064 | 0.040 |
Why?
| | Gene Deletion | 1 | 2021 | 389 | 0.040 |
Why?
| | Motor Activity | 1 | 2024 | 720 | 0.040 |
Why?
| | Recreation | 1 | 2019 | 26 | 0.040 |
Why?
| | Farmers | 1 | 2019 | 70 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 808 | 0.040 |
Why?
| | Arvicolinae | 1 | 2019 | 34 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2021 | 358 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 330 | 0.040 |
Why?
| | Texas | 1 | 2019 | 262 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1275 | 0.040 |
Why?
| | Arkansas | 1 | 2017 | 20 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1320 | 0.030 |
Why?
| | Arizona | 1 | 2017 | 81 | 0.030 |
Why?
| | Glanders | 1 | 2017 | 1 | 0.030 |
Why?
| | Typhus, Epidemic Louse-Borne | 1 | 2017 | 1 | 0.030 |
Why?
| | Melioidosis | 1 | 2017 | 5 | 0.030 |
Why?
| | Biological Warfare Agents | 1 | 2017 | 3 | 0.030 |
Why?
| | Anthrax | 1 | 2017 | 9 | 0.030 |
Why?
| | Smallpox | 1 | 2017 | 10 | 0.030 |
Why?
| | Botulism | 1 | 2017 | 8 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 346 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2017 | 128 | 0.030 |
Why?
| | Placenta | 1 | 2024 | 769 | 0.030 |
Why?
| | Knee Joint | 1 | 2020 | 411 | 0.030 |
Why?
| | Geography, Medical | 1 | 2016 | 11 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 11181 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 54 | 0.030 |
Why?
| | Georgia (Republic) | 1 | 2016 | 4 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 990 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2016 | 117 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 506 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 100 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 816 | 0.030 |
Why?
| | Mice | 2 | 2024 | 18109 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 951 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 987 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3071 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 397 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5909 | 0.020 |
Why?
| | Health Surveys | 1 | 2015 | 513 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 2012 | 33 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1977 | 0.020 |
Why?
| | Perinatal Care | 1 | 2012 | 61 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1820 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4421 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 663 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5637 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6966 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7777 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3508 | 0.010 |
Why?
|
|
Nelson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|